 Nathan Rabinovitch
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 27 | 2020 | 1805 | 3.840 |
Why?
| | Leukotriene E4 | 12 | 2018 | 24 | 2.840 |
Why?
| | Tobacco Smoke Pollution | 6 | 2020 | 227 | 1.630 |
Why?
| | Air Pollutants | 8 | 2020 | 407 | 1.610 |
Why?
| | Particulate Matter | 6 | 2020 | 329 | 1.520 |
Why?
| | Environmental Exposure | 8 | 2020 | 583 | 1.410 |
Why?
| | Anaphylaxis | 2 | 2024 | 105 | 1.250 |
Why?
| | Environmental Monitoring | 6 | 2016 | 347 | 1.040 |
Why?
| | Anti-Asthmatic Agents | 6 | 2018 | 264 | 1.010 |
Why?
| | Forced Expiratory Volume | 6 | 2015 | 451 | 0.900 |
Why?
| | Airway Obstruction | 2 | 2022 | 153 | 0.860 |
Why?
| | Leukotriene Antagonists | 4 | 2013 | 24 | 0.850 |
Why?
| | Air Pollution | 4 | 2020 | 315 | 0.850 |
Why?
| | Acetates | 5 | 2014 | 78 | 0.830 |
Why?
| | Quinolines | 5 | 2014 | 192 | 0.770 |
Why?
| | Endotoxins | 3 | 2015 | 217 | 0.730 |
Why?
| | Albuterol | 6 | 2016 | 76 | 0.720 |
Why?
| | Receptors, Leukotriene | 2 | 2020 | 13 | 0.710 |
Why?
| | Cannabis | 2 | 2019 | 518 | 0.670 |
Why?
| | Antigens, Plant | 2 | 2018 | 55 | 0.650 |
Why?
| | Air Pollution, Indoor | 3 | 2013 | 171 | 0.600 |
Why?
| | Nitric Oxide | 3 | 2015 | 892 | 0.590 |
Why?
| | Rhinitis, Allergic, Seasonal | 2 | 2017 | 25 | 0.560 |
Why?
| | Models, Statistical | 3 | 2013 | 677 | 0.550 |
Why?
| | Child | 24 | 2024 | 22980 | 0.550 |
Why?
| | Dermatitis, Atopic | 2 | 2023 | 322 | 0.550 |
Why?
| | Asthma, Exercise-Induced | 1 | 2018 | 14 | 0.550 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 9 | 0.540 |
Why?
| | Allergens | 2 | 2018 | 391 | 0.540 |
Why?
| | Vehicle Emissions | 1 | 2018 | 57 | 0.520 |
Why?
| | Angioedema | 1 | 2017 | 16 | 0.500 |
Why?
| | Emergency Medical Services | 1 | 2024 | 691 | 0.500 |
Why?
| | Regression Analysis | 3 | 2018 | 1003 | 0.490 |
Why?
| | Hypersensitivity | 1 | 2019 | 254 | 0.470 |
Why?
| | Longitudinal Studies | 3 | 2013 | 3029 | 0.470 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 168 | 0.460 |
Why?
| | Face | 1 | 2017 | 176 | 0.450 |
Why?
| | Biomarkers | 8 | 2018 | 4354 | 0.450 |
Why?
| | DNA Methylation | 1 | 2020 | 722 | 0.430 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 928 | 0.430 |
Why?
| | Bronchodilator Agents | 2 | 2013 | 187 | 0.430 |
Why?
| | Marijuana Smoking | 1 | 2018 | 249 | 0.420 |
Why?
| | Arachis | 1 | 2015 | 108 | 0.410 |
Why?
| | Peanut Hypersensitivity | 1 | 2015 | 143 | 0.390 |
Why?
| | Adrenergic beta-Agonists | 1 | 2013 | 92 | 0.390 |
Why?
| | Lung | 4 | 2022 | 4141 | 0.380 |
Why?
| | Humans | 38 | 2024 | 147306 | 0.350 |
Why?
| | Fungi | 1 | 2012 | 122 | 0.340 |
Why?
| | Risk | 4 | 2018 | 927 | 0.340 |
Why?
| | Cyclopropanes | 5 | 2014 | 84 | 0.330 |
Why?
| | Epinephrine | 2 | 2024 | 160 | 0.320 |
Why?
| | Sulfides | 5 | 2014 | 92 | 0.310 |
Why?
| | Adolescent | 13 | 2024 | 22826 | 0.270 |
Why?
| | Diet | 1 | 2015 | 1284 | 0.260 |
Why?
| | Personal Space | 1 | 2005 | 1 | 0.230 |
Why?
| | Cotinine | 2 | 2020 | 77 | 0.220 |
Why?
| | Israel | 1 | 2024 | 46 | 0.210 |
Why?
| | Male | 17 | 2024 | 73954 | 0.200 |
Why?
| | Androstadienes | 2 | 2014 | 77 | 0.200 |
Why?
| | Receptors, IgG | 1 | 2004 | 77 | 0.200 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 153 | 0.200 |
Why?
| | Pyrin | 1 | 2023 | 2 | 0.190 |
Why?
| | Public Health | 1 | 2008 | 577 | 0.190 |
Why?
| | Models, Theoretical | 1 | 2006 | 563 | 0.180 |
Why?
| | Monte Carlo Method | 2 | 2013 | 148 | 0.180 |
Why?
| | Inhalation Exposure | 2 | 2013 | 103 | 0.170 |
Why?
| | Female | 16 | 2024 | 80081 | 0.170 |
Why?
| | Smoking | 1 | 2008 | 1483 | 0.170 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 545 | 0.170 |
Why?
| | Particle Size | 3 | 2007 | 382 | 0.160 |
Why?
| | Antigens, CD | 1 | 2004 | 562 | 0.160 |
Why?
| | Dyspnea | 1 | 2022 | 252 | 0.160 |
Why?
| | Health Status | 1 | 2006 | 839 | 0.160 |
Why?
| | Polymorphism, Genetic | 1 | 2023 | 615 | 0.160 |
Why?
| | Models, Biological | 1 | 2007 | 1772 | 0.150 |
Why?
| | Exercise Test | 1 | 2022 | 636 | 0.150 |
Why?
| | Severity of Illness Index | 4 | 2011 | 2974 | 0.150 |
Why?
| | Soy Foods | 1 | 2018 | 3 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2004 | 878 | 0.140 |
Why?
| | Diet Therapy | 1 | 2018 | 36 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 232 | 0.130 |
Why?
| | Skin Tests | 1 | 2018 | 94 | 0.130 |
Why?
| | Disease Susceptibility | 2 | 2012 | 347 | 0.130 |
Why?
| | Causality | 1 | 2018 | 129 | 0.130 |
Why?
| | Pollen | 1 | 2017 | 18 | 0.130 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 590 | 0.130 |
Why?
| | Histamine Antagonists | 1 | 2017 | 21 | 0.130 |
Why?
| | Trees | 1 | 2017 | 60 | 0.130 |
Why?
| | Pruritus | 1 | 2017 | 60 | 0.130 |
Why?
| | Fluticasone | 2 | 2014 | 53 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2023 | 840 | 0.120 |
Why?
| | Computer Systems | 1 | 2016 | 55 | 0.120 |
Why?
| | Geographic Information Systems | 1 | 2016 | 45 | 0.120 |
Why?
| | Steroids | 1 | 2017 | 162 | 0.120 |
Why?
| | Immunization | 1 | 2018 | 375 | 0.120 |
Why?
| | Cities | 1 | 2016 | 140 | 0.120 |
Why?
| | User-Computer Interface | 1 | 2016 | 165 | 0.110 |
Why?
| | Administration, Oral | 1 | 2018 | 874 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2011 | 2133 | 0.110 |
Why?
| | Disease Progression | 2 | 2018 | 2892 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2014 | 617 | 0.100 |
Why?
| | Young Adult | 2 | 2024 | 14437 | 0.100 |
Why?
| | Colorado | 2 | 2016 | 4591 | 0.100 |
Why?
| | Salmeterol Xinafoate | 1 | 2013 | 20 | 0.100 |
Why?
| | Eczema | 1 | 2014 | 66 | 0.100 |
Why?
| | Nitrogen Dioxide | 1 | 2013 | 45 | 0.100 |
Why?
| | Leukocyte Count | 1 | 2013 | 319 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 293 | 0.090 |
Why?
| | Child, Preschool | 4 | 2024 | 12017 | 0.090 |
Why?
| | Linear Models | 2 | 2011 | 852 | 0.090 |
Why?
| | Mutation | 1 | 2023 | 4130 | 0.090 |
Why?
| | Nebulizers and Vaporizers | 1 | 2011 | 63 | 0.080 |
Why?
| | Eosinophils | 1 | 2013 | 319 | 0.080 |
Why?
| | Nicotine | 1 | 2013 | 336 | 0.080 |
Why?
| | Markov Chains | 1 | 2011 | 132 | 0.080 |
Why?
| | Pilot Projects | 1 | 2016 | 1912 | 0.080 |
Why?
| | Drug Utilization | 1 | 2011 | 171 | 0.080 |
Why?
| | Urban Health | 2 | 2013 | 96 | 0.080 |
Why?
| | Administration, Inhalation | 1 | 2011 | 572 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2011 | 502 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 200 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 487 | 0.070 |
Why?
| | Computer Simulation | 1 | 2013 | 1018 | 0.070 |
Why?
| | Immunoglobulin E | 1 | 2010 | 316 | 0.070 |
Why?
| | Age of Onset | 1 | 2010 | 568 | 0.070 |
Why?
| | Breath Tests | 1 | 2008 | 77 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2791 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 593 | 0.060 |
Why?
| | Sulfates | 1 | 2007 | 45 | 0.060 |
Why?
| | Maximum Allowable Concentration | 1 | 2006 | 16 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2009 | 575 | 0.060 |
Why?
| | Software | 1 | 2011 | 683 | 0.060 |
Why?
| | Retrospective Studies | 1 | 2024 | 17561 | 0.060 |
Why?
| | Epidemiological Monitoring | 1 | 2006 | 70 | 0.060 |
Why?
| | Calibration | 1 | 2006 | 153 | 0.060 |
Why?
| | Meteorological Concepts | 1 | 2004 | 6 | 0.050 |
Why?
| | Iron | 1 | 2007 | 361 | 0.050 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2004 | 20 | 0.050 |
Why?
| | Budesonide | 1 | 2004 | 49 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 24 | 0.050 |
Why?
| | Tetanus | 1 | 2004 | 29 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 70 | 0.050 |
Why?
| | Aged | 1 | 2024 | 26516 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 126 | 0.050 |
Why?
| | Cold Temperature | 1 | 2004 | 207 | 0.050 |
Why?
| | School Health Services | 1 | 2006 | 222 | 0.050 |
Why?
| | Pituitary-Adrenal System | 1 | 2004 | 166 | 0.050 |
Why?
| | Middle Aged | 2 | 2024 | 36821 | 0.050 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2004 | 201 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2004 | 762 | 0.050 |
Why?
| | Schools | 1 | 2005 | 453 | 0.040 |
Why?
| | Research Design | 1 | 2008 | 1158 | 0.040 |
Why?
| | Sex Factors | 1 | 2008 | 2136 | 0.040 |
Why?
| | Adult | 2 | 2024 | 41406 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5478 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2007 | 1171 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1845 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2004 | 1172 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 6164 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3784 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2416 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2010 | 11947 | 0.030 |
Why?
| | Cohort Studies | 1 | 2006 | 6099 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 7 | 0.030 |
Why?
| | Baltimore | 1 | 2013 | 72 | 0.020 |
Why?
| | United States | 1 | 2011 | 16313 | 0.020 |
Why?
| | Drug Combinations | 1 | 2014 | 399 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 402 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 11017 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 2017 | 0.010 |
Why?
| | Aerosols | 1 | 2004 | 147 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3448 | 0.010 |
Why?
| | Prospective Studies | 1 | 2013 | 8166 | 0.010 |
Why?
| | Patient Compliance | 1 | 2004 | 591 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2004 | 2080 | 0.010 |
Why?
|
|
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|